Investigational Drug Information for Sutezolid
✉ Email this page to a colleague
What is the development status for investigational drug Sutezolid?
Sutezolid is an investigational drug.
There have been 6 clinical trials for Sutezolid.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2023.
The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and [disabled in preview]. The leading clinical trial sponsors are Global Alliance for TB Drug Development, Sequella, Inc., and University of California, San Francisco.
There are twenty-one US patents protecting this investigational drug and two hundred and eighty-five international patents.
Summary for Sutezolid
| US Patents | 21 |
| International Patents | 285 |
| US Patent Applications | 103 |
| WIPO Patent Applications | 90 |
| Japanese Patent Applications | 14 |
| Clinical Trial Progress | Phase 1 (2023-01-01) |
| Vendors | 43 |
Recent Clinical Trials for Sutezolid
| Title | Sponsor | Phase |
|---|---|---|
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis | TB Alliance | Phase 2 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis | Global Alliance for TB Drug Development | Phase 2 |
Clinical Trial Summary for Sutezolid
Top disease conditions for Sutezolid
Top clinical trial sponsors for Sutezolid
US Patents for Sutezolid
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Sutezolid | ⤷ Sign Up | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Sign Up |
| Sutezolid | ⤷ Sign Up | Compounds, compositions and methods | Denali Therapeutics Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Sutezolid | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Sutezolid | ⤷ Sign Up | Anti-huLRRC15 antibody drug conjugates and methods for their use | AbbVie Inc. (North Chicago, IL) AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Sign Up |
| Sutezolid | ⤷ Sign Up | Anti-huLRRC15 antibody drug conjugates and methods for their use | AbbVie Inc. (North Chicago, IL) AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Sign Up |
| Sutezolid | ⤷ Sign Up | Tricyclic benzoxaborole compounds and uses thereof | GlaxoSmithKline Intellectual Property (No. 2) Limited (Brentford, Middlesex, GB) Anacor Pharmaceuticals, Inc. (Palo Alto, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Sutezolid
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Sutezolid | Australia | AU2015339012 | 2034-10-31 | ⤷ Sign Up |
| Sutezolid | Brazil | BR112017008945 | 2034-10-31 | ⤷ Sign Up |
| Sutezolid | Canada | CA2966005 | 2034-10-31 | ⤷ Sign Up |
| Sutezolid | European Patent Office | EP3212668 | 2034-10-31 | ⤷ Sign Up |
| Sutezolid | Spain | ES2832711 | 2034-10-31 | ⤷ Sign Up |
| Sutezolid | Japan | JP2017537893 | 2034-10-31 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
